R21 Malaria Investigational Vaccine

R21* is a protein-based investigational vaccine developed by the University of Oxford, using our Matrix-M™ adjuvant technology.¹ This investigational vaccine is specifically designed to help protect against malaria.

Malaria remains a significant global burden of disease,² infecting 247 million people worldwide in 2021 alone, with an estimated 619, 000 deaths. Developing additional malaria vaccines is urgently needed to address this threat.¹

R21 has been evaluated in safety and efficacy trials in both adults and children.¹

*Investigational vaccine created and trial sponsored by University of Oxford in collaboration with Serum Institute of India, with Matrix-M adjuvant.

• 1

  Genetic material is combined

  CSP gene is combined with the HBsAg protein gene to form a CSP-HBsAg recombinant DNA.

  
• 2

  Entry through electroporation

  The recombinant DNA is inserted into a plasmid and the genetic material enters the yeast cell.

  
• 3

  Stable recombination gene enters yeast cell nucleus

  The gene of interest is also inserted into the yeast genome to make a stable cell line.

  
• 4

  Yeast cell expresses fusion proteins

  Lysis buffer is used to break down yeast cell membranes and release proteins.

  
• 5

  Vaccine virus-like particle formation

  Fusion proteins self-assemble into virus-like particles. Fusion proteins are purified based on their size and density.

  
• 6

  Final vaccine

  R21 Virus-like particles are mixed with Matrix-M^TM adjuvant to create ready-to-use Malaria vaccine.